Navigation Links
BioDelivery Sciences Announces Upcoming Presentations at Three Investor Conferences
Date:8/31/2011

RALEIGH, N.C., Aug. 31, 2011 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) today announced its participation at three upcoming investor conferences.  Dr. Mark A. Sirgo, President and Chief Executive Officer, will present at each conference where he will focus on BDSI's product pipeline, particularly BEMA Buprenorphine for the treatment of chronic pain, for which data from the pivotal Phase 3 efficacy study is anticipated in late September, and BEMA Buprenorphine/Naloxone for the treatment of opioid dependence.  

(Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO)


  • William Blair 2011 Life Sciences Conference
    Wednesday, September 7 at 12:10 PM Eastern Time (Panel)
    The Intercontinental New York Barclay, New York City

  • Stifel Nicolaus 2011 Healthcare Conference
    Thursday, September 8 at 2:05 PM Eastern Time
    Four Seasons Hotel, Boston

  • Rodman & Renshaw Annual Global Investment Conference
    Tuesday, September 13 at 10:00 AM Eastern Time
    The Waldorf-Astoria, New York City
  • Both the Stifel Nicolaus 2011 Healthcare Conference and the Rodman & Renshaw Annual Global Investment Conference presentations will be webcast live and can be accessed at www.bdsi.com.  For those who are not available to listen to the live broadcast, the presentations will be archived.

    About BioDelivery Sciences InternationalBioDelivery Sciences International (NASDAQ: BDSI) is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics.  BDSI is focusing on developing products to meet unmet patient needs in the areas of pain management and oncology supportive care.  BDSI's pain franchise currently consists of two products utilizing the patented BEMA technology.  ONSOLIS (fentanyl buccal soluble film) is approved in the U.S., Canada, and the E.U. (where it will be marketed as BREAKYL), for the management of breakthrough pain in opioid tolerant, adult patients with cancer.  The commercial rights are licensed to Meda for all territories worldwide except for Taiwan (licensed to TTY Biopharm) and South Korea (licensed to Kunwha Pharmaceutical Co.).  BDSI's second pain product, BEMA Buprenorphine, is being developed for the treatment of moderate to severe chronic pain and is in development in a high dose formulation for the treatment of opioid dependence.  Additional product candidates are being developed utilizing the BEMA technology for conditions such as nausea/vomiting (BEMA Granisetron).  BDSI's headquarters is located in Raleigh, North Carolina.  For more information, visit www.bdsi.com.

    BDSI® and BEMA® are registered trademarks of BioDelivery Sciences International, Inc.  ONSOLIS® is a registered trademark of Meda Pharmaceuticals, Inc.  BREAKYL is registered trademark of Meda Pharma GmbH & Co. KG.

    Cautionary Note on Forward-Looking StatementsThis press release, the presentation described herein and the statements of representatives and partners of BioDelivery Sciences International, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission.  Actual results (including, without limitation, the results of the clinical studies of BEMA Buprenorphine and BEMA Buprenorphine/Naloxone and regulatory review of such products) may differ significantly from those set forth or implied in the forward-looking statements. These forward-looking statements involve significant risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control).  The Company undertakes no obligation to publically update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.  Readers are cautioned that peak sales and market size estimates have been determined on the basis of market research and comparable product analysis, but no assurances can be given that such estimates are accurate or that such sales levels will be achieved, if at all.


    '/>"/>

    SOURCE BioDelivery Sciences International, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. MonoSol Rx, LLC Files Patent Infringement and False Marking Lawsuit Against BioDelivery Sciences International, Inc., MEDA Pharmaceuticals Inc., and Aveva Drug Delivery Systems, Inc.
    2. BioDelivery Sciences Announces BEMA Buprenorphine Phase 3 Chronic Pain Study More Than 50% Recruited and on Schedule
    3. BioDelivery Sciences Confirms 505(b)(2) Pathway for BEMA Buprenorphine/Naloxone for Opioid Dependence Following FDA Meeting
    4. BioDelivery Sciences to Present at the 23rd Annual ROTH OC Growth Stock Conference
    5. BioDelivery Sciences Announces Completion of Recruitment in BEMA Buprenorphine Phase 3 Chronic Pain Study
    6. BioDelivery Sciences Provides Update on Status of Modified REMS Program for ONSOLIS
    7. BioDelivery Sciences to Present at the Jeffries Global Healthcare Conference
    8. BioDelivery Sciences Announces Commercial Launch of ONSOLIS in Canada
    9. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
    10. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
    11. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/5/2016)... , Feb. 5, 2016  As people age, ... The multitude of recommended screenings and tests that are ... a priority. However, for the majority of aging individuals, ... health planning. For the 37.5 million American adults who ... the present to make hearing health a 2016 healthy ...
    (Date:2/5/2016)... , Feb. 5, 2016  Aralez Pharmaceuticals Inc. ("Aralez") ... POZEN Inc. ("POZEN") and Tribute Pharmaceuticals Canada Inc. ("Tribute") following ... shareholders of Tribute. The combined company will operate under ... with operations in Canada , ... States . Under the terms of the Agreement ...
    (Date:2/5/2016)... , Feb. 5, 2016 Aethlon Medical, Inc. (Nasdaq: ... Chairman and CEO, will be presenting at Source Capital Group,s ... York, NY at 2:15 p.m. ET on Wednesday, ... Immunotherapy Panel discussion taking place at 3:15 p.m. ET. ... approximately one hour after the conclusion of the live event. ...
    Breaking Medicine Technology:
    (Date:2/8/2016)... ... 2016 , ... FileHold's document management software has been implemented ... hosted environment for FileHold software that is pay per user subscription-based and also ... the FileHold web services API. DocuSyst also advises clients on fully functioning back ...
    (Date:2/8/2016)... ... February 08, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to ... are derived from a cluster of melanin when exposed to sunlight. Although most moles ... a lifetime of embarrassment. Historically, mole removal has involved a painful, often ...
    (Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... (NADL), only four states in the U.S. require dental technicians to be certified ... in the dental industry, NADL created the “What’s In Your Mouth?” campaign to ...
    (Date:2/7/2016)... ... February 07, 2016 , ... ... has added Kybella® to his medical and surgical expertise. Technically known as deoxycholic ... injectable medication used as a non-surgical alternative for reduction of fat below the ...
    (Date:2/6/2016)... ... February 06, 2016 , ... Shark Finds and ... launch of a new DRTV campaign with Belly Bands. , Having a dog is ... sprays to puppy pads and find nothing works, get Belly Bands, the easiest ...
    Breaking Medicine News(10 mins):